Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo

Pobierz rekord bibliograficzny (.ris)

TABLE WITHOUT ID
  this.creators AS "Autor / redaktor",
  this.title AS "Tytuł",
  this.itemType AS "Typ",
  this.publication AS "Publikacja",
  this.year AS "Rok",
  this.doi AS "DOI",
  this.url AS "URL"
WHERE file.path = this.file.path

Abstract

Compared patient age and gender subpopulations on the basis of remission and response rates associated with venlafaxine and selective serotonin reuptake inhibitor (SSRI) treatment. A meta-analysis of original data from 8 comparable double-blind, active-controlled, randomized clinical trials was conducted. Antidepressant efficacy was assessed for 2,045 patients (aged 18-83 yrs) who met Diagnostic and Statistical Manual of Mental Disorders-III-Revised (DSM-III-R) criteria for major depression or Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria for major depressive disorder and were randomly assigned to receive venlafaxine, 1 of several SSRIs, or placebo for up to 8 wks. Symptoms of depression were assessed using the Hamilton Rating Scale for Depression (HAM-D). Remission was defined as a HAM-D-17 score ≤7, response was defined as ≥50% decrease in HAM-D-21 score, and absence of depressed mood was defined as a HAM-D depressed mood item score of 0. Results show no significant age-by-treatment, gender-by-treatment, or age-by-gender-by-treatment interactions; men and women of different ages within a given antidepressant treatment group exhibited similar rates of remission, response, and absence of depressed mood. Remission rates during venlafaxine therapy were higher than during SSRI therapy. Onset of remission was more rapid with venlafaxine than with SSRI treatment. (PsycINFO Database Record (c) 2016 APA, all rights reserved)

Notes